Date: 2015-06-09
Type of information: Nomination
Compound:
Company: Cerenis Therapeutics (USA)
Therapeutic area: Cardiovascular diseases - Metabolic diseases
Type agreement: nomination
Action mechanism:
Disease:
Details: * On June 9, 2015, Cerenis Therapeutics, an international biopharmaceutical company dedicated to the discovery and development of innovative HDL therapies (“good cholesterol”) for treating cardiovascular and metabolic diseases, announced the completion of its Board of Directors. At the last Board Meeting, Catherine Moukheibir and Dr. Laura A. Coruzzi were appointed to the Board of Directors replacing Healthcap’s representative, Johan Christenson, and Olivier Martinez, Bpifrance’s representative who becomes a Board Observer. Following these changes, the Board of Directors will consist of Richard Pasternak, Chairman of the Board of Directors, Jean-Louis Dasseux, CEO, Denis Lucquin, representative of Sofinnova, Michael H. Davidson, Marc Rivière, representative of TVM, Christian Chavy, Olivier Martinez, Board observer, along with Catherine Moukheibir and Laura Coruzzi. Most importantly, all Board members hold strong expertise within the field of healthcare and have extensive operating experience. Catherine Moukheibir, MA, MBA (from Yale University), has 20 years of experience in finance including 15 in the biotechnology industry, holding multiple leadership roles and Board roles. At Innate Pharma, where she is a member of the Executive Board, she was responsible for a major financial restructuring. Prior to joining Innate, Mrs Moukheibir was CFO of Movetis, a Belgian biotech company (from 2008 to 2010), for which she led the IPO on Euronext Brussels and then the acquisition by Shire. Previously, she was Director Capital Markets at Zeltia (from 2001 to 2007), a Spanish biopharma and consumer chemicals group, where she steered its financial strategy. Before joining Zeltia, she was a management consultant and then worked as an Executive Director for two major Investment Banks: Salomon Smith Barney and Morgan Stanley.
Dr. Laura Coruzzi Ph.D. is a member of the Intellectual Property practice at Jones Day, an international law firm. She has represented clients in biotechnology and pharmaceutical for 30 years, participating in numerous landmark cases. Laura\'s practice encompasses patent prosecution, litigation and appeals before the USPTO Board of Appeals, the Federal Circuit, and the U.S. Supreme Court. Prior to joining Jones Day, she practiced at Pennie & Edmonds LLP and was one of the first members of the firm\'s biotechnology group department founded by S. Leslie Misrock, affectionately known as the \"father of biotechnology patent law”. Her practice involves all aspects of patent law as it relates to a variety of disciplines in life sciences, including genetic engineering, molecular biology, virology, vaccines, immunology, therapeutic antibodies, biologic and small molecule therapeutics, diagnostics, drug discovery, and drug delivery. She is also well versed in the field of HDL and cardiovascular disease as she has been deeply involved in developing patent strategies related to HDL mimetics and Reverse Lipid Transport (RLT) modulating drugs. Dr. Coruzzi earned her Ph.D. in Biology at Fordham University and completed a post-doctoral fellowship at the Mount Sinai School of Medicine before entering the practice of law.
Financial terms:
Latest news:
